- Home
- NABL vs ORIC Comparison
NABL vs ORIC Comparison
Compare NABL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NABL | ORIC |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.6M | 837.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NABL | ORIC |
|---|---|---|
| Price | $5.26 | $10.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $8.31 | ★ $19.73 |
| AVG Volume (30 Days) | 1.0M | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $511,430,000.00 | N/A |
| Revenue This Year | $11.04 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $4.15 | $4.52 |
| 52 Week High | $9.04 | $14.93 |
Technical Indicators
Market Signals| Indicator | NABL | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 45.07 |
| Support Level | $4.53 | $9.59 |
| Resistance Level | $5.44 | $10.31 |
| Average True Range (ATR) | 0.25 | 0.64 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 85.66 | 53.30 |
Price Performance
Historical ComparisonAbout NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.